FDA Grants First Interchangeable Biosimilar Status to Golimumab, Raising GMP Bar for Biosimilar Manufacturers

The FDA's approval of Immgolis (golimumab-sldi) as the first interchangeable biosimilar to Simponi and Simponi Aria on May 15, 2026, sets a new manufacturing benchmark: interchangeability designation demands a higher evidentiary threshold than standard biosimilar approval, with direct consequences for CMOs and biosimilar sponsors managing comparability protocols, switching-study data packages, and 21 CFR Part 211 compliance across production sites.

Interchangeability status requires demonstration that the product can be substituted at the pharmacy level without prescriber intervention, a designation that compresses the regulatory distance between the reference product and the biosimilar. For QA directors and plant heads, this translates to tighter process validation requirements, more rigorous analytical comparability exercises, and heightened scrutiny of any post-approval manufacturing changes under ICH Q10 pharmaceutical quality system principles.

The May approval sits within a broader pattern visible across the FDA's notable approvals list. Since late 2024, the agency has cleared multiple first-in-class and rare-disease therapies, including the first oral treatment for iron deficiency in pediatric patients (Accrufer), the first drug for thymidine kinase 2 deficiency (Kygevvi), and the first treatment for complement 3 glomerulopathy (Fabhalta), each carrying distinct manufacturing complexity profiles. Rare-disease approvals frequently involve small-batch production, specialized containment, and accelerated pathways that place additional pressure on validation documentation and sterility assurance programs.

For biosimilar manufacturers specifically, the golimumab interchangeability precedent follows the 2024 approvals of the first interchangeable biosimilars to Eylea (Yesafili, Opuviz) and to Prolia and Xgeva (Jubbonti, Wyost). Each approval in this category has progressively refined FDA's expectations around switching-study design and the analytical rigor required to support interchangeability claims, a trajectory that regulatory affairs leads should map against their own development pipelines now, not at the BLA submission stage.

The cumulative approval volume across rare disease, biologics, and biosimilar categories also signals sustained manufacturing site activity: each new molecular entity or biosimilar designation triggers a distinct inspection readiness cycle, and facilities supporting multiple concurrent programs face compounding demands on their quality management systems.

The golimumab interchangeability approval will serve as a reference point for the next wave of biosimilar sponsors preparing switching-study protocols and seeking comparable designation for high-volume immunology biologics.

Source: FDA Drugs Notable Approvals page via FDA.gov RSS Feed, May 15, 2026.